Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

However, although the level of investment in pharmaceutical research and development (R&D) has increased dramatically during this period — to US$50 billion per year at present 1 — the number ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management ...

Agriculture, pharma, electronics, and engineering goods together accounted for over 50 per cent of India's merchandise exports in 2024-25, according to government data, highlighting the country's ...

"We are pleased to receive the FDA's approval of LED BLU-U and look forward to seeing the positive impact this next generation device will have for those living with actinic keratosis," said Abhay ...

If you’re on the fence about investing in BioCryst Pharmaceuticals, Inc., TG Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before ...

Melbourne Pharma Logo Redefining modern healthcare for Gen Z Melbourne Pharma is redefining healthcare for Gen Z in Florida with personalized compounded medications for skincare, mental health, hormon ...

Melbourne Pharma is redefining healthcare for Gen Z in Florida with personalized compounded medications for skincare, mental health, hormone balance, and more! MELBOURNE, FL, UNITED STATES ...

Operator: Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A question-and ...

COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment ...

Ascendis Pharma A/S announced positive results from Week 214 of its Phase 2 PaTH Forward Trial, indicating that long-term treatment with TransCon PTH (palopegteriparatide) effectively maintains a ...